Clinical trial
GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for…
NCT00228839 · Emory University, Other · Completed
Key facts
| NCT number | NCT00228839 |
|---|---|
| Title | GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease |
| Official title | A Pediatric Phase I Pharmacokinetic Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease |
| Lead sponsor | Emory University, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease |
| Intervention type | Drug |
| Interventions | Infliximab |
| Completion | Oct 1, 2006 |
| First posted | Sep 29, 2005 |
| Last update posted | Jun 30, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: